Company · CIK 0001567514 · SIC 2834 — Pharmaceutical Preparations
Intra-Cellular Therapies, Inc. · ITCI
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2019 SForm 4 → | Mar 1, 7:41 pm EST | Lawrence J. HinelineSVP of Finance CFO | 1,000 | $15.00 | $15,000 | 25,232 | −3.81% | plan? |
| Feb 27, 2019 MForm 4 → | Mar 1, 7:41 pm EST | Lawrence J. HinelineSVP of Finance CFO | 10,400 | $2.74 | $28,496 | 26,232 | — | plan? |
| Jan 4, 2019 SForm 4 → | Jan 8, 9:28 pm EST | Sharon MatesChairman, President & CEO, Director | 52,202 | $11.58 | $604,310 | 1,138,707 | −4.38% | plan? |
| Jan 4, 2019 MForm 4 → | Jan 8, 9:28 pm EST | Sharon MatesChairman, President & CEO, Director | 6,604 | — | — | 1,190,909 | — | plan? |
| Jan 4, 2019 SForm 4 → | Jan 8, 9:24 pm EST | Michael HalsteadEVP and General Counsel | 24,566 | $11.58 | $284,418 | 191 | −99.2% | plan? |
| Jan 4, 2019 MForm 4 → | Jan 8, 9:24 pm EST | Michael HalsteadEVP and General Counsel | 3,108 | — | — | 24,757 | — | plan? |
| Jan 4, 2019 SForm 4 → | Jan 8, 9:21 pm EST | Lawrence J. HinelineSVP of Finance CFO | 24,566 | $11.58 | $284,383 | 17,032 | −59.1% | plan? |
| Jan 4, 2019 GMForm 4 → | Jan 8, 9:21 pm EST | Lawrence J. HinelineSVP of Finance CFO | 4,308 | — | — | 15,832 | — | plan? |
| Jan 4, 2019 SForm 4 → | Jan 8, 9:19 pm EST | Kimberly E. VanoverSVP, Early Stage Clinical Dev. | 10,156 | $11.52 | $116,979 | 27,068 | −27.3% | plan? |
| Jan 4, 2019 MForm 4 → | Jan 8, 9:19 pm EST | Kimberly E. VanoverSVP, Early Stage Clinical Dev. | 1,554 | — | — | 37,224 | — | plan? |
| Jan 4, 2019 SForm 4 → | Jan 8, 9:16 pm EST | Robert E DavisSVP, Chief Scientific Officer | 9,564 | $11.46 | $109,630 | 43,989 | −17.9% | plan? |
| Jan 2, 2019 SForm 4 → | Jan 3, 9:02 pm EST | Sharon MatesChairman, President & CEO, Director | 17,478 | $11.09 | $193,831 | 1,138,707 | −1.51% | plan? |
| Jan 2, 2019 SForm 4 → | Jan 3, 8:58 pm EST | Michael HalsteadEVP and General Counsel | 7,807 | $11.09 | $86,580 | 191 | −97.6% | plan? |
| Jan 2, 2019 SForm 4 → | Jan 3, 8:46 pm EST | Kimberly E. VanoverSVP, Early Stage Clinical Dev. | 4,834 | $11.10 | $53,657 | 16,861 | −22.3% | plan? |
| Jan 2, 2019 SForm 4 → | Jan 3, 8:42 pm EST | Robert E DavisSVP, Chief Scientific Officer | 4,834 | $11.11 | $53,706 | 34,744 | −12.2% | plan? |
| Jan 2, 2019 SForm 4 → | Jan 3, 8:23 pm EST | Lawrence J. HinelineSVP of Finance CFO | 7,807 | $11.09 | $86,580 | 17,032 | −31.4% | plan? |
| Dec 31, 2018 AMForm 4 → | Jan 3, 2019, 9:02 pm EST | Sharon MatesChairman, President & CEO, Director | 63,076 | — | — | 1,184,305 | — | plan? |
| Dec 31, 2018 AMForm 4 → | Jan 3, 2019, 8:58 pm EST | Michael HalsteadEVP and General Counsel | 29,265 | — | — | 21,649 | — | plan? |
| Dec 31, 2018 AMForm 4 → | Jan 3, 2019, 8:46 pm EST | Kimberly E. VanoverSVP, Early Stage Clinical Dev. | 28,131 | — | — | 35,670 | — | plan? |
| Dec 31, 2018 AMForm 4 → | Jan 3, 2019, 8:42 pm EST | Robert E DavisSVP, Chief Scientific Officer | 28,131 | — | — | 53,553 | — | plan? |
| Dec 31, 2018 AMForm 4 → | Jan 3, 2019, 8:23 pm EST | Lawrence J. HinelineSVP of Finance CFO | 29,265 | — | — | 38,490 | — | plan? |
| Dec 31, 2018 AForm 4 → | Jan 3, 2019, 8:19 pm EST | Robert L Van NostrandDirector | 512 | $11.39 | $5,832 | 4,955 | — | plan? |
| Dec 31, 2018 AForm 4 → | Jan 3, 2019, 8:15 pm EST | Rory B RiggsDirector | 1,273 | $11.39 | $14,499 | 40,057 | — | plan? |
| Dec 31, 2018 AForm 4 → | Jan 3, 2019, 8:11 pm EST | Richard A LernerDirector | 1,207 | $11.39 | $13,748 | 11,430 | — | plan? |
| Dec 31, 2018 AForm 4 → | Jan 3, 2019, 8:05 pm EST | Christopher D AlafiDirector | 1,273 | $11.39 | $14,499 | 748,916 | — | plan? |
| Dec 10, 2018 MForm 4 → | Dec 11, 5:55 pm EST | Sharon MatesChairman, President & CEO, Director | 50,000 | $1.50 | $75,000 | 1,138,707 | — | plan? |
| Dec 6, 2018 SForm 4 → | Dec 7, 4:44 pm EST | Robert E DavisSVP, Chief Scientific Officer | 899 | $13.53 | $12,163 | 30,256 | −2.89% | plan? |
| Dec 4, 2018 MForm 4 → | Dec 7, 4:44 pm EST | Robert E DavisSVP, Chief Scientific Officer | 1,758 | — | — | 31,155 | — | plan? |
| Nov 9, 2018 SForm 4 → | Nov 13, 5:34 pm EST | Joel S MarcusDirector | 32,000 | $18.17 | $581,580 | 78,742 | −28.9% | plan? |
| Oct 22, 2018 MForm 4 → | Oct 24, 4:33 pm EDT | Richard A LernerDirector | 12,500 | $1.50 | $18,750 | 66,911 | — | plan? |
| Sep 30, 2018 AForm 4 → | Oct 2, 8:11 pm EDT | Richard A LernerDirector | 633 | $21.70 | $13,736 | 54,411 | — | plan? |
| Sep 30, 2018 AForm 4 → | Oct 2, 8:08 pm EDT | Rory B RiggsDirector | 668 | $21.70 | $14,496 | 38,784 | — | plan? |
| Sep 30, 2018 AForm 4 → | Oct 2, 8:06 pm EDT | Robert L Van NostrandDirector | 268 | $21.70 | $5,816 | 4,443 | — | plan? |
| Sep 30, 2018 AForm 4 → | Oct 2, 8:01 pm EDT | Christopher D AlafiDirector | 668 | $21.70 | $14,496 | 747,643 | — | plan? |
| Jun 29, 2018 AForm 4 → | Jul 3, 4:27 pm EDT | Richard A LernerDirector | 778 | $17.67 | $13,747 | 53,778 | — | plan? |
| Jun 29, 2018 AForm 4 → | Jul 3, 4:22 pm EDT | Robert L Van NostrandDirector | 282 | $17.67 | $4,983 | 4,175 | — | plan? |
| Jun 29, 2018 AForm 4 → | Jul 3, 4:20 pm EDT | Rory B RiggsDirector | 820 | $17.67 | $14,489 | 38,116 | — | plan? |
| Jun 29, 2018 AForm 4 → | Jul 3, 4:17 pm EDT | Christopher D AlafiDirector | 820 | $17.67 | $14,489 | 746,975 | — | plan? |
| Mar 30, 2018 AForm 4 → | Apr 3, 4:35 pm EDT | Christopher D AlafiDirector | 688 | $21.05 | $14,482 | 746,155 | — | plan? |
| Mar 30, 2018 AForm 4 → | Apr 3, 4:33 pm EDT | Richard A LernerDirector | 653 | $21.05 | $13,746 | 10,223 | — | plan? |
| Mar 30, 2018 AForm 4 → | Apr 3, 4:31 pm EDT | Rory B RiggsDirector | 688 | $21.05 | $14,482 | 37,296 | — | plan? |
| Mar 30, 2018 AForm 4 → | Apr 3, 4:19 pm EDT | Robert L Van NostrandDirector | 237 | $21.05 | $4,989 | 3,893 | — | plan? |
| Feb 15, 2018 SForm 4 → | Feb 20, 4:38 pm EST | Lawrence J. HinelineVP of Finance CFO | 49,700 | $20.02 | $995,165 | 17,032 | −74.5% | plan? |
| Jan 22, 2018 SForm 4 → | Jan 24, 7:11 pm EST | Michael HalsteadSVP and General Counsel | 25,500 | $18.03 | $459,765 | 191 | −99.3% | plan? |
| Jan 8, 2018 SForm 4 → | Jan 10, 9:05 pm EST | Kimberly E. VanoverSVP, Clinical Development | 772 | $17.46 | $13,479 | 12,373 | −5.87% | plan? |
| Jan 8, 2018 SForm 4 → | Jan 10, 9:01 pm EST | Sharon MatesChairman, President & CEO, Director | 6,604 | $17.48 | $115,438 | 1,088,707 | −0.60% | plan? |
| Jan 5, 2018 SForm 4 → | Jan 5, 8:19 pm EST | Sharon MatesChairman, President & CEO, Director | 11,257 | $17.08 | $192,270 | 1,095,311 | −1.02% | plan? |
| Jan 5, 2018 SForm 4 → | Jan 5, 8:14 pm EST | Kimberly E. VanoverSVP, Clinical Development | 1,185 | $17.37 | $20,583 | 13,145 | −8.27% | plan? |
| Jan 4, 2018 SForm 4 → | Jan 5, 8:09 pm EST | Robert E DavisSVP, Chief Scientific Officer | 1,115 | $15.60 | $17,394 | 29,397 | −3.65% | plan? |
| Jan 4, 2018 SForm 4 → | Jan 5, 8:06 pm EST | Lawrence J. HinelineVP of Finance CFO | 5,062 | $16.34 | $82,725 | 66,732 | −7.05% | plan? |
| Jan 4, 2018 SForm 4 → | Jan 5, 8:03 pm EST | Michael HalsteadSVP and General Counsel | 4,220 | $16.39 | $69,179 | 25,691 | −14.1% | plan? |
| Jan 3, 2018 MForm 4 → | Jan 5, 8:19 pm EST | Sharon MatesChairman, President & CEO, Director | 17,861 | — | — | 1,106,568 | — | plan? |
| Jan 3, 2018 MForm 4 → | Jan 5, 8:14 pm EST | Kimberly E. VanoverSVP, Clinical Development | 4,202 | — | — | 14,330 | — | plan? |
| Jan 3, 2018 MForm 4 → | Jan 5, 8:09 pm EST | Robert E DavisSVP, Chief Scientific Officer | 2,648 | — | — | 30,512 | — | plan? |
| Jan 3, 2018 MForm 4 → | Jan 5, 8:06 pm EST | Lawrence J. HinelineVP of Finance CFO | 8,405 | — | — | 71,794 | — | plan? |
| Jan 3, 2018 MForm 4 → | Jan 5, 8:03 pm EST | Michael HalsteadSVP and General Counsel | 8,405 | — | — | 29,911 | — | plan? |
| Dec 29, 2017 AForm 4/A → | Jan 3, 2018, 6:10 pm EST | Robert L Van NostrandDirector | 345 | $14.48 | $4,996 | 3,656 | — | plan? |
| Dec 29, 2017 AForm 4/A → | Jan 3, 2018, 6:05 pm EST | Rory B RiggsDirector | 1,001 | $14.48 | $14,494 | 36,608 | — | plan? |
| Dec 29, 2017 AForm 4/A → | Jan 3, 2018, 6:01 pm EST | Richard A LernerDirector | 949 | $14.48 | $13,742 | 9,570 | — | plan? |
| Dec 29, 2017 AForm 4/A → | Jan 3, 2018, 5:59 pm EST | Christopher D AlafiDirector, 10% Owner | 1,001 | $14.48 | $14,494 | 745,467 | — | plan? |
| Dec 29, 2017 PForm 4 → | Jan 3, 2018, 4:31 pm EST | Robert L Van NostrandDirector | 345 | $14.48 | $4,996 | 3,656 | +10.4% | plan? |
| Dec 29, 2017 PForm 4 → | Jan 3, 2018, 4:31 pm EST | Rory B RiggsDirector | 1,001 | $14.48 | $14,494 | 36,608 | +2.81% | plan? |
| Dec 29, 2017 PForm 4 → | Jan 3, 2018, 4:29 pm EST | Richard A LernerDirector | 949 | $14.48 | $13,742 | 9,570 | +11.0% | plan? |
| Dec 29, 2017 PForm 4 → | Jan 3, 2018, 4:28 pm EST | Christopher D AlafiDirector, 10% Owner | 1,001 | $14.48 | $14,494 | 745,467 | +0.13% | plan? amended |
| Dec 11, 2017 SForm 4 → | Dec 13, 4:52 pm EST | Richard A LernerDirector | 7,000 | $15.09 | $105,630 | 53,000 | −11.7% | plan? |
| Dec 11, 2017 MForm 4 → | Dec 13, 4:52 pm EST | Richard A LernerDirector | 12,500 | $1.50 | $18,750 | 60,000 | — | plan? |
| Dec 5, 2017 SForm 4 → | Dec 6, 6:33 pm EST | Robert E DavisSVP, Chief Scientific Officer | 650 | $15.00 | $9,750 | 27,864 | −2.28% | plan? |
| Dec 4, 2017 MForm 4 → | Dec 6, 6:33 pm EST | Robert E DavisSVP, Chief Scientific Officer | 1,757 | — | — | 28,514 | — | plan? |
| Nov 22, 2017 PForm 4 → | Nov 27, 4:31 pm EST | Christopher D AlafiDirector, 10% Owner | 10,000 | $15.55 | $155,500 | 744,466 | +1.36% | plan? |
| Oct 30, 2017 SForm 4 → | Nov 1, 8:04 pm EDT | Sharon MatesChairman, President & CEO, Director | 18,750 | $15.75 | $295,313 | 1,088,707 | −1.69% | plan? |
| Oct 30, 2017 MForm 4 → | Nov 1, 8:04 pm EDT | Sharon MatesChairman, President & CEO, Director | 18,750 | $1.50 | $28,125 | 1,107,457 | — | plan? |
| Oct 2, 2017 PForm 4 → | Oct 3, 6:11 pm EDT | Moshe Alafi10% Owner | 258,065 | $15.50 | $4,000,008 | 3,953,270 | +6.98% | plan? |
| Oct 2, 2017 PForm 4 → | Oct 3, 6:10 pm EDT | Christopher D AlafiDirector, 10% Owner | 258,065 | $15.50 | $4,000,008 | 3,953,270 | +6.98% | plan? |
| Oct 2, 2017 PForm 4 → | Oct 3, 6:08 pm EDT | ALAFI CAPITAL CO LLC10% Owner | 258,065 | $15.50 | $4,000,008 | 3,953,270 | +6.98% | plan? |
| Sep 29, 2017 AForm 4 → | Oct 3, 6:19 pm EDT | Robert L Van NostrandDirector | 316 | — | — | 3,311 | — | plan? |
| Sep 29, 2017 AForm 4 → | Oct 3, 6:17 pm EDT | Rory B RiggsDirector | 918 | — | — | 35,607 | — | plan? |
| Sep 29, 2017 AForm 4 → | Oct 3, 6:14 pm EDT | Richard A LernerDirector | 871 | — | — | 8,621 | — | plan? |
| Sep 29, 2017 AForm 4 → | Oct 3, 6:10 pm EDT | Christopher D AlafiDirector, 10% Owner | 918 | — | — | 734,466 | — | plan? |
| Jun 30, 2017 AForm 4 → | Jul 5, 6:29 pm EDT | Richard A LernerDirector | 1,107 | — | — | 7,750 | — | plan? |
| Jun 30, 2017 AForm 4 → | Jul 5, 6:07 pm EDT | Robert L Van NostrandDirector | 402 | — | — | 2,995 | — | plan? |
| Jun 30, 2017 AForm 4 → | Jul 5, 6:05 pm EDT | Rory B RiggsDirector | 1,167 | — | — | 34,689 | — | plan? |
| Jun 30, 2017 AForm 4 → | Jul 5, 4:35 pm EDT | Christopher D AlafiDirector, 10% Owner | 1,167 | — | — | 733,548 | — | plan? |
| Mar 31, 2017 AForm 4 → | Apr 4, 5:02 pm EDT | Robert L Van NostrandDirector | 307 | — | — | 2,593 | — | plan? |
| Mar 31, 2017 AForm 4 → | Apr 4, 4:54 pm EDT | Rory B RiggsDirector | 892 | — | — | 33,522 | — | plan? |
| Mar 31, 2017 AForm 4 → | Apr 4, 4:51 pm EDT | Richard A LernerDirector | 846 | — | — | 6,643 | — | plan? |
| Mar 31, 2017 AForm 4 → | Apr 4, 4:35 pm EDT | Christopher D AlafiDirector, 10% Owner | 892 | — | — | 732,381 | — | plan? |
| Jan 26, 2017 GMForm 4 → | Jan 30, 6:13 pm EST | Joel S MarcusDirector | 285,000 | $2.60 | $247,450 | 110,742 | — | plan? |
| Jan 5, 2017 SForm 4 → | Jan 9, 5:34 pm EST | Kimberly E. VanoverSVP, Clinical Development | 800 | $16.59 | $13,272 | 10,128 | −7.32% | plan? |
| Jan 5, 2017 SForm 4 → | Jan 9, 5:31 pm EST | Sharon MatesChairman, President & CEO, Director | 4,081 | $16.55 | $67,541 | 1,088,707 | −0.37% | plan? |
| Jan 5, 2017 SForm 4 → | Jan 9, 5:29 pm EST | Lawrence J. HinelineVP of Finance CFO | 1,918 | $16.58 | $31,800 | 63,389 | −2.94% | plan? |
| Jan 5, 2017 SForm 4 → | Jan 9, 5:27 pm EST | Michael HalsteadSVP and General Counsel | 1,601 | $16.55 | $26,497 | 21,506 | −6.93% | plan? |
| Jan 4, 2017 MForm 4 → | Jan 5, 6:00 pm EST | Kimberly E. VanoverSVP, Clinical Development | 1,553 | — | — | 10,928 | — | plan? |
| Jan 4, 2017 MForm 4 → | Jan 5, 5:58 pm EST | Sharon MatesChairman, President & CEO, Director | 6,603 | — | — | 1,092,788 | — | plan? |
| Jan 4, 2017 MForm 4 → | Jan 5, 5:56 pm EST | Lawrence J. HinelineVP of Finance CFO | 3,107 | — | — | 65,307 | — | plan? |
| Jan 4, 2017 MForm 4 → | Jan 5, 5:54 pm EST | Michael HalsteadSVP and General Counsel | 3,107 | — | — | 23,107 | — | plan? |
| Dec 30, 2016 AForm 4 → | Jan 3, 2017, 4:33 pm EST | Robert L Van NostrandDirector | 331 | — | — | 2,286 | — | plan? |
| Dec 30, 2016 AForm 4 → | Jan 3, 2017, 4:31 pm EST | Rory B RiggsDirector | 960 | — | — | 32,630 | — | plan? |
| Dec 30, 2016 AForm 4 → | Jan 3, 2017, 4:26 pm EST | Joel S MarcusDirector | 994 | — | — | 21,671 | — | plan? |
| Dec 30, 2016 AForm 4 → | Jan 3, 2017, 4:23 pm EST | Richard A LernerDirector | 911 | — | — | 5,797 | — | plan? |
| Dec 30, 2016 AForm 4 → | Jan 3, 2017, 4:19 pm EST | Christopher D AlafiDirector, 10% Owner | 960 | — | — | 731,489 | — | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2019 MForm 4 → | Mar 1, 7:41 pm EST | Lawrence J. HinelineSVP of Finance CFO | 10,400 | — | — | 9,600 | — | |
| Jan 8, 2019 AForm 4 → | Jan 10, 4:28 pm EST | Andrew SatlinEVP and Chief Medical Officer | 163,178 | — | — | 68,735 | — | |
| Jan 8, 2019 AForm 4 → | Jan 10, 4:18 pm EST | Mark NeumannEVP, Chief Commercial Officer | 149,191 | — | — | 62,843 | — | |
| Jan 8, 2019 AForm 4 → | Jan 8, 9:16 pm EST | Robert E DavisSVP, Chief Scientific Officer | 130,542 | — | — | 54,988 | — | |
| Jan 4, 2019 AMForm 4 → | Jan 8, 9:28 pm EST | Sharon MatesChairman, President & CEO, Director | 304,988 | — | — | 125,687 | — | |
| Jan 4, 2019 AMForm 4 → | Jan 8, 9:24 pm EST | Michael HalsteadEVP and General Counsel | 142,974 | — | — | 58,915 | — | |
| Jan 4, 2019 AMForm 4 → | Jan 8, 9:21 pm EST | Lawrence J. HinelineSVP of Finance CFO | 142,974 | — | — | 58,915 | — | |
| Jan 4, 2019 AMForm 4 → | Jan 8, 9:19 pm EST | Kimberly E. VanoverSVP, Early Stage Clinical Dev. | 141,420 | — | — | 58,915 | — | |
| Jan 3, 2019 MForm 4 → | Jan 3, 9:02 pm EST | Sharon MatesChairman, President & CEO, Director | 45,598 | — | — | 68,681 | — | |
| Jan 3, 2019 MForm 4 → | Jan 3, 8:58 pm EST | Michael HalsteadEVP and General Counsel | 21,458 | — | — | 32,320 | — | |
| Jan 3, 2019 MForm 4 → | Jan 3, 8:46 pm EST | Kimberly E. VanoverSVP, Early Stage Clinical Dev. | 18,809 | — | — | 32,320 | — | |
| Jan 3, 2019 MForm 4 → | Jan 3, 8:42 pm EST | Robert E DavisSVP, Chief Scientific Officer | 18,809 | — | — | 32,320 | — | |
| Jan 3, 2019 MForm 4 → | Jan 3, 8:23 pm EST | Lawrence J. HinelineSVP of Finance CFO | 21,458 | — | — | 32,320 | — | |
| Dec 10, 2018 MForm 4 → | Dec 11, 5:55 pm EST | Sharon MatesChairman, President & CEO, Director | 50,000 | — | — | 0 | — | |
| Dec 4, 2018 MForm 4 → | Dec 7, 4:44 pm EST | Robert E DavisSVP, Chief Scientific Officer | 1,758 | — | — | 0 | — | |
| Oct 22, 2018 MForm 4 → | Oct 24, 4:33 pm EDT | Richard A LernerDirector | 12,500 | — | — | 0 | — | |
| Oct 15, 2018 AForm 4 → | Oct 17, 4:28 pm EDT | Mark NeumannEVP, Chief Commercial Officer | 95,644 | — | — | 40,344 | — | |
| Jun 18, 2018 AForm 4 → | Jun 20, 4:52 pm EDT | Rory B RiggsDirector | 14,189 | — | — | 14,189 | — | |
| Jun 18, 2018 AForm 4 → | Jun 20, 4:49 pm EDT | Joel S MarcusDirector | 14,189 | — | — | 14,189 | — | |
| Jun 18, 2018 AForm 4 → | Jun 20, 4:47 pm EDT | Robert L Van NostrandDirector | 20,000 | — | — | 20,000 | — | |
| Jun 18, 2018 AForm 4 → | Jun 20, 4:45 pm EDT | Richard A LernerDirector | 20,000 | — | — | 20,000 | — | |
| Jun 18, 2018 AForm 4 → | Jun 20, 4:40 pm EDT | Christopher D AlafiDirector | 20,000 | — | — | 20,000 | — | |
| Jan 3, 2018 AMForm 4 → | Jan 5, 8:19 pm EST | Sharon MatesChairman, President & CEO, Director | 259,355 | — | — | 103,021 | — | |
| Jan 3, 2018 AMForm 4 → | Jan 5, 8:14 pm EST | Kimberly E. VanoverSVP, Clinical Development | 117,846 | — | — | 48,480 | — | |
| Jan 3, 2018 AMForm 4 → | Jan 5, 8:09 pm EST | Robert E DavisSVP, Chief Scientific Officer | 116,292 | — | — | 48,480 | — | |
| Jan 3, 2018 AMForm 4 → | Jan 5, 8:06 pm EST | Lawrence J. HinelineVP of Finance CFO | 122,049 | — | — | 48,480 | — | |
| Jan 3, 2018 AMForm 4 → | Jan 5, 8:03 pm EST | Michael HalsteadSVP and General Counsel | 122,049 | — | — | 48,480 | — | |
| Dec 11, 2017 MForm 4 → | Dec 13, 4:52 pm EST | Richard A LernerDirector | 12,500 | — | — | 0 | — | |
| Dec 4, 2017 MForm 4 → | Dec 6, 6:33 pm EST | Robert E DavisSVP, Chief Scientific Officer | 1,757 | — | — | 1,758 | — | |
| Nov 13, 2017 AForm 4 → | Nov 15, 5:13 pm EST | Andrew SatlinEVP and Chief Medical Officer | 170,500 | — | — | 170,500 | — | |
| Oct 30, 2017 MForm 4 → | Nov 1, 8:04 pm EDT | Sharon MatesChairman, President & CEO, Director | 18,750 | — | — | 0 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 4:26 pm EDT | Robert L Van NostrandDirector | 20,000 | — | — | 20,000 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 4:24 pm EDT | Rory B RiggsDirector | 20,000 | — | — | 20,000 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 4:22 pm EDT | Joel S MarcusDirector | 20,000 | — | — | 20,000 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 4:20 pm EDT | Richard A LernerDirector | 20,000 | — | — | 20,000 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 4:18 pm EDT | Christopher D AlafiDirector, 10% Owner | 20,000 | — | — | 20,000 | — | |
| Jan 26, 2017 MForm 4 → | Jan 30, 6:13 pm EST | Joel S MarcusDirector | 95,000 | — | — | 0 | — | |
| Jan 3, 2017 AMForm 4 → | Jan 5, 6:00 pm EST | Kimberly E. VanoverSVP, Clinical Development | 41,357 | — | — | 3,108 | — | |
| Jan 3, 2017 AMForm 4 → | Jan 5, 5:58 pm EST | Sharon MatesChairman, President & CEO, Director | 175,775 | — | — | 13,208 | — | |
| Jan 3, 2017 AMForm 4 → | Jan 5, 5:56 pm EST | Lawrence J. HinelineVP of Finance CFO | 82,717 | — | — | 6,216 | — | |
| Jan 3, 2017 AMForm 4 → | Jan 5, 5:54 pm EST | Michael HalsteadSVP and General Counsel | 82,717 | — | — | 6,216 | — | |
| Dec 15, 2016 MForm 4 → | Dec 19, 5:50 pm EST | Kimberly E. VanoverSVP, Clinical Development | 18,750 | — | — | 0 | — | |
| Dec 4, 2016 AMForm 4 → | Jan 5, 2017, 5:47 pm EST | Robert E DavisSVP, Chief Scientific Officer | 41,561 | — | — | 7,946 | — | late |
| Jun 14, 2016 AForm 4 → | Jun 15, 4:27 pm EDT | Christopher D AlafiDirector, 10% Owner | 20,000 | — | — | 20,000 | — | |
| Jun 14, 2016 AForm 4 → | Jun 15, 4:26 pm EDT | Rory B RiggsDirector | 20,000 | — | — | 20,000 | — | |
| Jun 14, 2016 AForm 4 → | Jun 15, 4:24 pm EDT | Richard A LernerDirector | 20,000 | — | — | 20,000 | — | |
| Jun 14, 2016 AForm 4 → | Jun 15, 4:23 pm EDT | Joel S MarcusDirector | 20,000 | — | — | 20,000 | — | |
| Jun 14, 2016 AForm 4 → | Jun 15, 4:22 pm EDT | Robert L Van NostrandDirector | 20,000 | — | — | 20,000 | — | |
| Feb 18, 2016 MForm 4 → | Feb 19, 4:25 pm EST | Richard A LernerDirector | 10,000 | — | — | 0 | — | |
| Jan 4, 2016 AForm 4/A → | Apr 4, 5:05 pm EDT | Lawrence J. HinelineVP of Finance CFO | 48,630 | — | — | 9,323 | — | |
| Jan 4, 2016 AForm 4 → | Jan 6, 8:29 pm EST | Lawrence J. HinelineVP of Finance CFO | 48,630 | — | — | 9,323 | — | amended |
| Jan 4, 2016 AForm 4 → | Jan 6, 8:27 pm EST | Michael HalsteadSVP and General Counsel | 48,630 | — | — | 9,323 | — | |
| Jan 4, 2016 AForm 4 → | Jan 6, 8:25 pm EST | Sharon MatesChairman, President & CEO, Director | 103,339 | — | — | 19,811 | — | |
| Jan 4, 2016 AForm 4 → | Jan 6, 8:24 pm EST | Kimberly E. VanoverVP, Clinical Development | 24,314 | — | — | 4,661 | — | |
| Dec 22, 2015 GForm 4 → | Dec 23, 6:21 pm EST | Richard A LernerDirector | 290,000 | — | — | 20,000 | — | |
| Dec 11, 2015 MForm 4 → | Dec 15, 8:27 pm EST | Sharon MatesChairman, President & CEO, Director | 68,750 | — | — | 18,750 | — | |
| Dec 4, 2015 AForm 4 → | Dec 8, 5:33 pm EST | Robert E DavisSVP, Chief Scientific Officer | 27,502 | — | — | 5,272 | — | |
| Nov 24, 2015 MForm 4 → | Dec 15, 8:25 pm EST | Lawrence J. HinelineVP of Finance CFO | 47,500 | — | — | 0 | — | late |
| Sep 9, 2015 MForm 4 → | Sep 11, 4:53 pm EDT | Allen A. FienbergVP of Business Development | 12,500 | — | — | 0 | — | |
| Jun 16, 2015 AForm 4 → | Jun 22, 5:26 pm EDT | Robert L Van NostrandDirector | 20,000 | — | — | 20,000 | — | late |
| Jun 16, 2015 AForm 4 → | Jun 22, 5:24 pm EDT | Rory B RiggsDirector | 20,000 | — | — | 20,000 | — | late |
| Jun 16, 2015 AForm 4 → | Jun 22, 5:21 pm EDT | Joel S MarcusDirector | 20,000 | — | — | 20,000 | — | late |
| Jun 16, 2015 AForm 4 → | Jun 22, 5:20 pm EDT | Richard A LernerDirector | 20,000 | — | — | 20,000 | — | late |
| Jun 16, 2015 AForm 4 → | Jun 22, 5:19 pm EDT | Christopher D AlafiDirector, 10% Owner | 20,000 | — | — | 20,000 | — | late |
| May 19, 2015 MForm 4 → | May 20, 5:19 pm EDT | Lawrence P. WennogleVice President, Drug Discovery | 47,500 | — | — | 0 | — | |
| Mar 31, 2015 MForm 4 → | Apr 2, 4:59 pm EDT | Allen A. FienbergVP of Business Development | 12,500 | — | — | 0 | — | |
| Mar 31, 2015 MForm 4 → | Apr 2, 4:58 pm EDT | Joel S MarcusDirector | 15,000 | — | — | 0 | — | |
| Jan 2, 2015 AForm 4 → | Jan 6, 5:19 pm EST | Juan F. SanchezVP, Corp. Communications & IR | 30,050 | — | — | 30,050 | — | |
| Jan 2, 2015 AForm 4 → | Jan 6, 5:19 pm EST | Lawrence P. WennogleVice President, Drug Discovery | 12,020 | — | — | 12,020 | — | |
| Jan 2, 2015 AForm 4 → | Jan 6, 5:18 pm EST | Allen A. FienbergVP of Business Development | 40,066 | — | — | 40,066 | — | |
| Jan 2, 2015 AForm 4 → | Jan 6, 5:18 pm EST | Kimberly E. VanoverVP, Clinical Development | 72,120 | — | — | 72,120 | — | |
| Jan 2, 2015 AForm 4 → | Jan 6, 5:17 pm EST | Lawrence J. HinelineVP of Finance CFO | 72,120 | — | — | 72,120 | — | |
| Jan 2, 2015 AForm 4 → | Jan 6, 5:17 pm EST | Michael HalsteadSVP and General Counsel | 88,146 | — | — | 88,146 | — | |
| Jan 2, 2015 AForm 4 → | Jan 6, 5:16 pm EST | Sharon MatesChairman, President & CEO, Director | 228,380 | — | — | 228,380 | — |